BRCA1 and breast cancer: These results indicate that BRCA1-defective breast cancer cells are highly responsive to CDDP treatment but resistant to Dox or Tax, suggesting a differential pattern of chemosensitivity specific for breast cancer cells with loss of BRCA1 function.